Want to see IN:TAKE full AI Analyst Report?
TAKE Stock Chart & Stats
₹20.76
₹0.05(0.24%)
At close: 4:00 PM EDT
₹20.76
₹0.05(0.24%)
Day’s Range― - ―
52-Week Range₹9.00 - ₹49.90
Previous CloseN/A
Volume250.59K
Average Volume (3M)58.94K
Market Cap
₹3.40B
Enterprise Value₹1.67K
Total Cash (Recent Filing)₹186.41M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)31.6
Beta1.28
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding147,934,000
10 Day Avg. Volume129,011
30 Day Avg. Volume58,943
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage: Reported Zero Debt In Recent YearsTAKE's reported zero total debt in FY2025–FY2026 materially reduces financial leverage and interest burden, improving liquidity flexibility. Over 2–6 months this gives management optionality to invest in product development, pursue M&A or absorb short-term cash volatility without debt-service constraints.
Focused Enterprise Software Exposure In Life Sciences & Supply ChainTAKE operates in specialized, regulation-driven software for clinical research, regulatory compliance, pharmacovigilance and supply-chain execution. These domains generate structurally recurring demand, high switching costs and long sales cycles that can support durable contract revenue and margin recovery with product-market fit.
Proven Ability To Generate Strong Free Cash Flow HistoricallyHistorical strong free cash flow in FY2021–FY2022 demonstrates the business can convert earnings to cash when operations scale and execution aligns. This track record suggests management can restore cash generation under improved margins or revenue mix, underpinning medium-term solvency and reinvestment potential.
Bears Say
Negative Operating Cash Flow Despite Reported Net IncomeOperating cash outflows amid positive net income indicate poor earnings quality and weak cash conversion. Persisting divergence constrains sustainable investments, forces reliance on financing or non-operating items, and raises risk that reported profits are not supporting operational funding over the medium term.
Core Operations Unprofitable: Negative Gross & Operating Profit In FY2026Negative gross and operating profits mean core product and service economics are loss-making, implying margins aren't sustainable without pricing, cost or mix changes. Reliance on below-the-line items to deliver net income masks fragile operational health and jeopardizes long-term margin recovery.
High Historical Volatility And Past Equity ImpairmentA history of negative equity and volatile earnings undermines financial predictability and could limit access to capital or raise funding costs. Such structural variability complicates planning, increases refinancing risk during stress, and reduces investor confidence over a multi-month horizon.
TAKE Solutions Limited News
TAKE FAQ
What was TAKE Solutions Limited’s price range in the past 12 months?
TAKE Solutions Limited lowest stock price was ₹9.00 and its highest was ₹49.90 in the past 12 months.
What is TAKE Solutions Limited’s market cap?
TAKE Solutions Limited’s market cap is ₹3.40B.
When is TAKE Solutions Limited’s upcoming earnings report date?
TAKE Solutions Limited’s upcoming earnings report date is Nov 05, 2026 which is in 85 days.
How were TAKE Solutions Limited’s earnings last quarter?
TAKE Solutions Limited released its earnings results on Aug 11, 2026. The company reported ₹0.072 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TAKE Solutions Limited overvalued?
According to Wall Street analysts TAKE Solutions Limited’s price is currently Overvalued.
Does TAKE Solutions Limited pay dividends?
TAKE Solutions Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on TAKE Solutions Limited dividends here
What is TAKE Solutions Limited’s EPS estimate?
TAKE Solutions Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TAKE Solutions Limited have?
TAKE Solutions Limited has 147,934,000 shares outstanding.
What happened to TAKE Solutions Limited’s price movement after its last earnings report?
TAKE Solutions Limited reported an EPS of ₹0.072 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.174%.
Which hedge fund is a major shareholder of TAKE Solutions Limited?
Currently, no hedge funds are holding shares in IN:TAKE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TAKE Solutions Limited
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―